Chemotherapy versus best supportive care for extensive small cell lung cancer

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  Alvarez, Marta Pelayo ^a   Rubio, Óscar Gallego ^b   Cosp, Xavier Bonfill ^c,d   Varela, Yolanda Agra ^e  

^a Atención Primaria Área 11 ^*  (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e Agencia de Calidad del SNS   (Spain)

Author keywords

Antineoplastic combined chemotherapy protocols *therapeutic use ; Carcinoma; Humans; Ifosfamide therapeutic use ; Lomustine therapeutic use ; Lung neoplasms *drug therapy ; Randomized controlled trials as topic; Small cell *drug therapy; pathology

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LOMUSTINE; METHOTREXATE; PICOPLATIN; PLATINUM DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE;

ANEMIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DYSPNEA; EVALUATION; FATIGUE; HAIR LOSS; HUMAN; INFECTION; LEUKOPENIA; LUNG SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; QUALITY OF LIFE; REVIEW; SEPSIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 77950117425     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001990.pub2     Document Type: Review

References (88)

1. Kokron 1977b {published data only} Kokron O, Titscher R, Micksche M, Cerni C, Wrba H. Clinical experiences with Holoxan in small ceIl carcinoma of the bronchus (authors transl). Osterreichische Kneipp Magazin 1977;15:103-8.
2. Kokron 1982 {published data only} Kokron O, Mickshe M, Titscher R, Wrba H. Ifosfamide versus ifosfamide + CCNU in the treatment of inoperable small cell lung cancer. A clinical study. Onkologie 1982;56:56-9.
3. O'Brien 2006 {published data only} O'Brien MER, Ciuleanu TE, Tsekov H, Shparyk Y, Cucevia B, Juhasz G, et al.Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed smallcell lung cancer. Journal of Clinical Oncology 2006;24:5441-7.
4. Spiro 1989 {published data only} Spiro SG, Souhami RL, Geddes DM, Ash CM, Quinn H, Harper PG, et al.Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. British Journal of Cancer 1989;59: 578-83.
5. AlIan 1984 {published data only} Allan SG, Gregor A, Cornbleet MA, Leonard RC, Smyth JF, Grant IW, et al.Phase II trial of vindesine and VP16-213 in the palliation of poor-prognosis patients and elderly patients with small cell lung cancer. Cancer Chemotherapy and Pharmacology 1984;13:106-8.
6. Anderson 1993 {published data only} Anderson FI, Hopwood P, Prendiville J, Radford JA, Thatcher N, Ashcroft L. A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer. British Journal of Cancer 1993;67:1385-90.
7. Ardizzoni 2002 {published data only} Ardizzoni A, Tjan-Heijnen VCG, Postmus PE, Buchholz E, Biesma B, Karnicka Mlodkowska FI, et al.Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: A prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group phase III trial-08923. Journal of Clinical Oncology 2002;20:3947-55.
8. Beith 1996 {published data only} Beith JM, Clarke SJ, Woods RL, Bell DR, Levi JA. Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung. European Journal of Cancer 1996;32A:438-43.
9. Bleehen 1989 {published data only} Bleehen NM, Fayers PM, Girling DJ, Stephens RJ. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small cell lung cancer. British Journal of Cancer 1989;59:584-90.
10. Bleehen 1993 {published data only} Bleehen NM, Girling DJ, Machin D, Stephens RJ. A randomised trial of three or six courses of etoposide, cyclophosphamide, methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life. Medical Research Council Lung Cancer Working Party. British Journal of Cancer 1993;68:1157-66.
11. Bleehen 1996 {published data only} Bleehen NM, Girling D, Hopwood P, Lallemand G, Machin D, Stephens RI, et al.Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. British Journal of Cancer 1996;73:406-13.
12. Candido 2002 {published data only} Candido P, Cavallaro G, Piatti G, Bucchioni E. Results of a combined phase II study on small celI lung cancer. Giornale Italiano Delle Malattie del Torace 2002;56:105-12.
13. Ciuleanu 2002 {published data only} Ciuleanu TE, Curca R, Iancu D, Todor N, Cebotaru C, Fadulescu I, et al.First-Iine chemotherapy with topotecan and etoposide in advanced small cell lung cancer. A phase II study. Journal of the Balkan Union of Oncology 2002;7:43-6.
14. CuIlen 1986 {published data only} Cullen M, Morgan D, Gregory W, Robinson M, Cox D, McGivern D, et al.Maintenance chemotherapy for anaplastic small celI carcinoma of the bronchus: a randomised, controlled trial. Cancer Chemotherapy & Pharmacology 1986;17:157-60.
15. EarI 1991 {published data only} Earl HM, Rudd RM, Spiro SG, Ash CM, James LE, Law CS, et al.A randomised trial of planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. British Journal of Cancer 1991;64:566-72.
16. Eridani 1978 {published data only} Eridani S, Burdick L, Maggio L, Cunietti E, Periti M, Arosio A, et al.Combined chemotherapy for unresectable carcinoma of the lung: a randomized trial. International Journal of Clinical Pharmacology & Biopharmacy 1978;16:182-5.
17. Ettinger 1990 {published data only} Ettinger DS, Finkelstein DM, Abeloff MD, Ruckdeschel JC, Aisner SC, Eggleston JC. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology 1990;8:230-40.
18. Giaccone 1993 {published data only} Giaccone G, Dalesio O, McVie GJ, Kirkpatrick A, Postmus PE, Burghouts JTh, et al.Maintenance chemotherapy in small cell lung cancer: long-term results of a randomized trial. Journal of Clinical Oncology 1993;11:1230-40.
19. Green 1969 {published data only} Green R, Humphrey E, Close H, Patno M. Alkylating Agents in Bronchogenic Carcinoma. American Journal of Medicine 1969;46: 516-25.
20. GrideIIi 2002 {published data only} Gridelli C, Rossi A, Barletta E, Panza N, Brancaccio L, Cioffi R, et al.Carboplatin plus vinorelbine plus G-CSF in elderly patients with extensive-stage small-cell lung cancer: a poorly tolerated regimen. Results of a multicentre phase II study. Lung Cancer 2002;36: 327-32.
21. Hainsworth 2002 {published data only} Hainsworth ID, Morrissey LH, Scullin DC ir, Houston GA, Prasthofer EF, Gray JR, et al.Paclitaxel, carboplatin, and topotecan in the treatment of patients with small celI lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer 2002; 94:2426-33.
22. Hanna 2002 {published data only} Hanna NH, Sandler AB, Loehrer PJ, Ansari R, Jung SH, lane K, et al.Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Annals of Oncology 2002;13: 95-102.
23. James 1996 {published data only} James LE, Gower NH, Rudd RM, Spiro SG, Harper PG, Trask CW, et al.A randomised trial of low-dose/high-frequency chemotherapy as palliative treatment of poor-prognosis small-ceIl lung cancer: a Cancer research Campaign trial. British Journal of Cancer 1996;73:1563-8.
24. Joss 1995 {published data only} Joss RA, Alberto P, Hurny C, Bacchi M, Leyvraz S, Thurlimann B, et al.Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK). Annals of Oncology 1995;6:41-8.
25. Kokron 1974a {published data only} Kokron O. [Die Behandlung des kleinzelligen metastasierenden Bronchuskarzinoms mit Ifosfamid. Ergebnisse einer prospectiven randomisierten Studie]. Österreichische Zeitschrift für Onkologie 1974;5-6:123-7.
26. Kokron 1974b {published data only} Kokron O. Treatment of oat cell metastazing bronchial carcinoma with isofosfamide. Results of a prospective randomized study [Die Behandlung des kleinzelligen Bronchuskarzinoms]. Osterreichische Kneipp Magazin 1974;5-6:123-7.
27. Kokron 1977a {published data only} Kokron O. [Klinische Erfahrungen mit Holoxan beim kleinzelligen Bronchuskarzinom]. Österreichische Zeitschrift für Onkologie 1977; 4:103-6.
28. Korfel 2002 {published data only} Korfel A, Oehm C, von Pawel J, Keppler U, Deppermann M, Kaubitsch S, et al.Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after wholebrain irradiation. A multicentre phase II study. European Journal of Cancer 2002;38:1724-9.
29. Lebeau 1992 {published data only} Lebeau B, Chastang Cl, Allard P, Migueres J, Boita F, Fichet D, et al.Six vs twelve cycles for complete responders to chemotherapy in small cell lung cancer: definitive results of a randomized clinical trial. European Respiratory Journal 1992;5:286-90.
30. Lyss 2002 {published data only} Lyss AP, Herndon lI JE, Lynch Jr TJ, Turrisi AT, Watson DM, Grethlein SJ, et al.Novel doublets in extensive-stage small-cell lung cancer: A randomized phase II study of topotecan plus cisplatin of paclitaxel (CALGB 9430). Clinical Lung Cancer 2002;3:205-10.
31. Mattson 1992 {published data only} Mattson K, Niiranen A, Pyrhönen S, Holsti LR, Holsti P, Kumpulainen E, et al.Natural interferon alfa as maintenance therapy for small cell lung cancer. European Journal of Cancer 1992; 28A:1387-91.
32. Mattson 1997 {published data only} Mattson K, Niiranen A, Ruotsalainen T, Maasilta P, Halme M, Pyrhönen, et al.Interferon maintenance therapy for small cell lung cancer: improvement in long-term survival. Journal of Interferon and cytokine research 1997;17:103-5.
33. Maurer 1980 {published data only} Maurer LH, Tulloh M, Weiss RB, Blom J, Leone L, Glidewell O, et al.A randomized combined modality trial in small cell carcinoma of the lung. Cancer 1980;45:30-9.
34. Mok 2002 {published data only} Mok TS, Wong H, Zee B, Yu KH, Leung TW, Lee TW, et al.A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase 1 and II inhibitors) in the treatment of patients with small celI lung carcinoma. Cancer 2002;95:1511-19.
35. Naka 2002 {published data only} Naka N, KawaharaM, Okishio K, Hosoe S, OgawaraM, Atagi S, et al.Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer. Lung Cancer 2002;37:319-23.
36. Noda 2002 {published data only} Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al.Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. New England Journal of Medicine 2002;346:85-91.
37. Reck 1998 {published data only} Reck M, Haering B, Koschel G, Kaukel E, Von Pawel J, Gatzemeier U. Chemotherapy of advanced SCLC and NSCLC with Bendamustine - A phase II-study. Pneumologie 1998;52:570-3.
38. Rosenthal 1991 {published data only} Rosenthal M, Kefford R, Raghavan D, Stuart-Harris R. Epirubicin: a phase II study in recurrent small-cell lung cancer. Cancer Chemotherapy and Pharmacology 1991;28:220-2.
39. Schiller 2001 {published data only} Schiller JH, Adak S, Cella D, DeVore RF, Johnson DH. Topotecan versus observation alter cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593- A phase III trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology 2001; 19:2114-22.
40. Sculier 1996 {published data only} Sculier JP, Paesmans M, Bureau G, Giner V, Lecomte J, Michel J, et al.Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. Journal of Clinical Oncology 1996;14: 2337-44.
41. Smit 1989 {published data only} Smit EF, Carney DN, Harford P, Sleijfer DT, Postmus PE. A phase II study of oral etoposide in elderly patients with small cell lung cancer. Thorax 1989;44:631- 3.
42. Souhami 1997 {published data only} Souhami RL, Spiro SG, Rudd RM, Ruiz de Elvira MC, James LE, Gower NH, et al.Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. Journal of the National Cancer Institute 1997;89: 577-80.
43. Sundstrom 2002 {published data only} Sundstrom S, Bremnes RM, Kaasa S, Aasebo U, Hatlevoll R, Dahle R, et al.Norwegian Lung Cancer Study Group. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years follow-up. Journal of Clinical Oncology 2002;20:4665-72.
44. Tada 2002 {published data only} Tada A, Ueoka H, Kiura K, Tabata M, Takemoto M, Yamane H, et al.Combination chemotherapy with carboplatin and etoposide for elderly patients aged 76 years or older with small cell lung cancer. [Japanese]. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy] 2002;29:751-6.
45. Thatcher 1996 {published data only} Thatcher N, Clark PI, Girling DJ, Hopwood P, Twiddy S, Stephens RJ, et al.Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped multicentre randomised trial. Lancet 1996;348:563-6.
46. Thomas 2002 {published data only} Thomas JP, Moore T, Kraut EH, Balcerzak SP, Galloway S, Vandre DD. A phase II study of CI-980 in previously untreated extensive small celI lung cancer: an Ohio State University phase II research consortium study. Cancer Investigation 2002;20:192-8.
47. Tjan-Heíjnen 2001 {published data only} Tjan-Heijnen VCG, Postmus PE, Ardizzoni A, Manegold Ch, Burghouts J, Van-Meerbeeck J, et al.Reduction of chemotherapyinduced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study. Annals of Oncology 2001;12:1359-68.
48. Vanseenkiste 2001 {published data only} Vansteenkiste J, Gatzemeier U, Manegold C, Hanauske A, Weynants P, Bosquée L, et al.Gemcitabine plus etoposide in chemonaive extensive disease small-ceIl lung cancer: A multi-centre phase II study. Annals of Oncology 2001;12:835-40.
49. von Pawel 1990 {published data only} von Pawel J, Wilke H, Vahee D, Dimbeck H, Schmohl HJ. Phase II study with etoposide/vincristine in small cell bronchial cancer (extensive disease), [Article in German]. Pneumologie 1990;44: 582-3.
50. Zhang 2002 {published data only} Zhang Z, Hu Z, Lu X, Zeng L. Evaluation of topotecan combined with cisplatin in the treatment of small cell Iung cancer. Chinese Journal of Lung Cancer 2002;5:354-6.
51. Picoplatin Study {published data only} A randomised, controlled phase III trial of picoplatin and BSC alone in patients with small cell lung cancer (SCLC), refractory or progressive within six months of completing first-line, platinumcontaining chemotherapy. Ongoing study April 2007.
52. Amarasena 2008 Amarasena IU, Walters JAE, Wood-Baker R, Fong K. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD006849.pub2]
53. Bernhard 1996 Bernhard J, Hürny C, Bacchi M, Joss RA, Cavalli F, Senn HJ, et al.Initial prognostic factors in small-celI lung cancer patients predicting quality of life during chemotherapy. British Journal of Cancer 1996;74:1660-7.
54. Carney 2002 Carney D. Lung cancer-Time to move on from chemotherapy. New England Journal of Medicine 2002;346:126-7.
55. Casciato 2000 Casciato D, Lowitz B. Manual of Clinical Oncology. Fourth. Philadelphia: Lippincott Williams & Wilkins, 2000.
56. Cheng 2007 Cheng S, Evans WK, Stys-Norman D, Shepherd FA, and the Lung Cancer Disease Site Group of Cancer Care Ontario' Program in Evidence-based Care. Chemotherapy for relapse small cell lung cancer: a systematic review and practice guideline. Journal of Thoracic Oncology 2007;2:348-54.
57. Chutte 1999 Chute J, Chen T, Feigal E, Simon R, Johnson B. Twenty years of phase III trials for patients with extensive-stage small celI lung cancer: perceptible progress. Journal of Clinical Oncology 1999;17: 1794-801.
58. Day 2000 Day SJ, Altman DG. Blinding in clinical trials and other studies. British Medical Journal 2000;321:504.
59. De Vita 2000 De Vita V, Hellan S, Rosemberg S. Cancer: Principles & Practice of Oncology. Sixth. Philadelphia: Lippincott, 2000.
60. De Wet 1994 De Wet M, Falkson G, Rapoport BL. Small cell Iung cancer: analysis of factors influencing the response to treatment and survival. Oncology 1994;51:523-34.
61. Dumville 2006 Dumville JC, Torgerson DJ, Hewitt CE. Reporting attrition in randomised controlled trials. British Medical Journal 2006;332: 969-71.
62. Froeschl 2008 Froeschl S, Nicholas G, Gallant V, Laurie SA. Outcomes of secondline chemotherapy in patients with relapsed extensive small cell lung cancer. Journal of Thoracic Oncology 2008;3:163-9.
63. Geddes 1990 Geddes DM, Dones L, Hill E, Law K, Harper PG, Spiro SG, et al.Quality of life during chemotherapy for small cell lung cancer: assessment and use of a daily diary card in a randomized trial. European Journal of Cancer 1990;26:484-92.
64. Govindan 2006 Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al.Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. Journal of Clinical Oncology 2006;24:4539-44.
65. Gralla 2004 Gralla RJ. Quality of life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life. The Oncologist 2004;9 (suppl 6):14-24.
66. Higgins 2008 Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.1 [updated September 2008].. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
67. Hollen 1994a Hollen Pi, Gralla RJ, Kris MG, Cox C, Belani CP, Grunberg SM, et al.Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. Cancer 1994;73:2087-98.
68. Hollen 1994b Hollen Pi, Gralla RJ, Kris MG, Cox C. Quality of life during clinical trials: conceptual model for the Lung Cancer Symtom Scale (LCSS). Supportive Care in Cancer 1994;2:213-22.
69. Ihde 1992 Ihde DC. Chemotherapy of lung cancer. New England Journal of Medicine 1992;327:1434-41.
70. Kim 2008 Kim YH, Goto K, Yoh K, Niho S, Ohmatsu H, Kubota K, et al.Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy. Cancer 2008;113: 2518-23.
71. Kleinbaum 1996 Kleinbaum DG. Survival analysis: A self-learning text. New York: Springer-Verlag, 1996.
72. Lacombe 1997 Lacombe D. Ethical Issues in cancer Clinical Trials: a European Perspective. European Journal of Cancer 1997;33:184-5.
73. Lassen 1998 Lassen, Hirsch FR, Osterlind K, Bergman B, Dombernoswky P. Outcome of combination chemotherapy in extensive stage smallcelI lung cancer: any treatment related progress?. Lung Cancer 1998;20:151-60.
74. Lexchin 2003 Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326:1167-76.
75. Manser 2003 Manser R, Irving LB, Stone C, Byrnes G, Abramson MJ, Campbell D. Screening for lung cancer. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/ 14651858.CD001991.pub2]
76. Moore 1998 Moore RA, Gevaghan D, Traver MR, Collins S, McQuay HJ. Size is everything. The impact of event rate variation on clinical trials and metaanalysis. Pain 1998;78:208-16.
77. O'Brien 2007 O'Brien M, Eckardt J, Ramlau R. Recent advances with topotecan in the treatment of lung cancer. The Oncologist 2007;12:1194-204.
78. Rawson 1990 Rawson NS, Peto J. An overview of prognostic factors in small cell Lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. British Journal of Cancer 1990;61:597-604.
79. Rothwell 2005 Rothwell PM. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 2005;365: 176-86.
80. Seidenfeld 2006 Seidenfeld J, Samson DJ, Bonnell CJ, Ziegler KM, Aronson N. Management of small cell lung cancer. Evidence Report/ Technology Assessment No 143. AHRQ Publication No. 06-E016. Rockville, MD: Agency for Health Research and Quality July 2006.
81. Souhami 1988 Souhami RL, Morittu L, Ash CM, EarI H, Geddes D, Harper PG, et al.Identification of patients at high risk of chemotherapy induced toxicity in SCLC. Antibiotics and Chemotherapy 1988;41:220-5.
82. Souhami 1990 Souhami RL, Law K. Longevity in small cell lung cancer. A report to the Lung Cancer SubCommitee of the United Kingdom Coordinating Commitee for Cancer Research. British Journal of Cancer 1990;61:584-9.
83. Sugiyama 2008 Sugiyama T, Hirose T, Hosaka T, Kusumoto S, Nakashima M, Yamaoka T, et al.Effectiveness of intensive follow-up after response in patients with small cell lung cancer. Lung Cancer 2008;59: 255-61.
84. Sundstr¢m 2005 Sundstr¢m S, Bremnes RM, Kaasa S, Aaseb¢ U, Aamdal S. Secondline chemotherapy in recurrent small lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen). Lung Cancer 2005;48:251-61.
85. Vrdoljak 2001 Vrdoljak E, Mise K, Sapunar A, Rozga A, Marusic M. Staging in untreated patients with small cell Iung cancer. Neoplasma 2001;48: 154-6.
86. Wolf 2004 Wolf M, Tebbe S, Fink T. First-line chemotherapy in metastatic small-cell lung cancer (SCLC). Lung Cancer 2004;Suppl 2: S223-S234.
87. Zelen 1973 Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemotherapy Reports. Part 3 1973;4:31-42.
88. Agra 2003 Agra Varela Y, Pelayo Alvarez M, Sacristan M, Sacristan Rodea A, Serra C, Bonfill Cosp X. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD001990]